论文部分内容阅读
[目的]探讨miR-1307的差异表达对卵巢癌紫杉醇耐药性的影响。[方法]Realtime PCR方法研究20例化疗耐药卵巢癌与20例化疗敏感卵巢癌组织及耐药与敏感卵巢癌细胞系(SKOV3-TR30和SKOV3)中miR-1307的表达情况;生物信息学方法预测miR-1307可能的靶基因及其靶基因的GO功能分析及通路分析。[结果]miR-1307在化疗耐药卵巢癌组织及细胞系中表达水平显著高于敏感组织及细胞系中,并且具有显著性(P<0.05,P<0.0001),其表达与卵巢癌患者绝经与否、手术病理分期、组织学分级及有无淋巴结转移无明显相关性(P>0.05);通过生物信息学分析,miR-1307的预测靶基因共124个,可能参与的生物学过程461个,分子功能80个,参与的信号通路15个。[结论]miR-1307与卵巢癌化疗耐药有关,可能通过相关的靶基因及其参与的生物学过程调节卵巢癌耐药。
[Objective] To investigate the effect of differential expression of miR-1307 on paclitaxel resistance in ovarian cancer. [Methods] The real-time PCR method was used to study the expression of miR-1307 in 20 cases of chemoresistant ovarian cancer and 20 cases of chemosensitive ovarian cancer and in the resistant and sensitive ovarian cancer cell lines (SKOV3-TR30 and SKOV3). The bioinformatics methods GO function analysis and pathway analysis of potential targets of miR-1307 and its target genes. [Results] The expression level of miR-1307 in chemoresistant ovarian cancer tissues and cell lines was significantly higher than that in sensitive tissues and cell lines (P <0.05, P <0.0001) There was no significant correlation between pathological stage, histological grade and lymph node metastasis (P> 0.05). According to bioinformatics analysis, there were 124 predicted target genes of miR-1307 and 461 possible biological processes involved , 80 molecular functions, 15 signal pathways involved. [Conclusion] miR-1307 is associated with chemoresistance in ovarian cancer, which may regulate the drug resistance of ovarian cancer through the related target genes and their involved biological processes.